Publications

  1. Pestring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM: Diversity of Organ Site Involvement Among Malignant Lymphomas of Mucosa-Associated Tissues (MALTomas). Am JClin Patho1.1991; 96:738-745.

 

  1. Essell JH, Thompson JM, Harman, GS: Marked Increase in Veno-Occlusive Disease of the Liver Associated with methotrexate Graft Versus Host Disease Prophylaxis in Patients Receiving Busulfan/Cyclophosphamide. Blood. 1992:79:2784-2788.

 

  1. Essell JH, Thompson JM, Harnlan GS: Pilot Trial of Prophylactic Ursodeoxycholic Acid to Prevent Veno[1]Occlusive Disease in Allogeneic Bone Marrow Transplant Patients. Bone Marrow Transplant. 1992; 10:367-372.

 

  1. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of Thromboelastography to Bleeding Time and Standard Coagulation Parameters in the Post Cardiopulmonary Bypass Patient. J Cardiothoracic Anesthesia. Aug 1993; 7:410-415.

 

  1. Snyder MJ, Johnson DB, Dayl MB, Giguere JK, Harman GS, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL, Rubinsak JR, Essell JH, Halvorson RD, and Thompson JM, Carmustine, Ara-c, Cyclophosphamide and Etoposide with Autologous Bone Marrow Transplantation in Relapsed or Refractory Lymphoma: A Dose -Finding Study, Bone Marrow Transplantation. 1994,14;595-600.

 

  1. Kereiakes DJ, Essell JH. Abciximab Associated Profound Thrombocytopenia and Therapy with Immune Globulin and Platelet Transfusion. Am J. Cardiology. 1996,78:1161-1163.

 

  1. Eisen D, Essell JH, Broun E. Oral Cavity Complications of Bone Marrow Transplantation. Seminars in Cutaneous Medicine and Surgery. 16,1997:265-272. Curriculum Vitae James H. Essell, M.D. Oncology/Hematology Care, Inc. Last Updated: October 10, 2018 Page 7

 

  1. Eisen D, Essell JH. Drug-Induced Thrombocytopenia Presenting with Isolated Oral Lesions: Report of Two Cases. Cutis 1998 Oct; 62(4):193-5.

 

  1. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, and Thomson JM. Prophylactic Ursodeoxycholic Acid for the Prevention of Hepatic Complications of Allogenic Bone Marrow Transplantation. A Randomized Controlled Trial. Annals of Internal Medicine 1998 June 15:128(12 Pt 1):975-81.

 

  1. Eisen D, Essell JH, Broun ER, Sigmund D, Devoe M. Clinical Utility of Oral Valacyclovir Compared with Oral Acyclovir for the Prevention of Herpes Simplex Virus Mucositis Following Autologous Bone Marrow Transplantation or Stem Cell Rescue Therapy. Bone Marrow Transplant. 2003 Jan;31(1):51-5.

 

  1. Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS. Phase II Trial of Vinorelbine for Relapsed Ovarian Cancer: A Southwest Oncology Group Study. Gynecologic Oncology. 004 Dec:95(3):506-12.

 

  1. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Collander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF. Denileukin Diftitox for the Treatment of Steroid-Resistant Acute Graft-vs.-Host Disease. Biology of Blood and Marrow Transplantation 2005 Mar: 11(3):188-93.

 

  1. Horwitz ME, Spasojevic I, Morris A, Telen M, Essell JH, Gasparetto C, Sullivan K, Long G, Chute J, Chao N, Rizzieri D. Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation. 2007 Aug:1422-26.

 

  1. Wagner-Johnson, N. Strickland, D.K., Wright, D. D., Tetreault, S.A., Lunin, S.D., Essell, J. H., & Marris, M. (2014, May). DYNAMO: A Phase 2 trial of the P13K- {delta}, {gamma} inhibitor IPI-145 in patients with refractory indolent Non-Hodgkin Lymphoma. In ASCO Annual Meeting Proceedings (Vol.32, No 15_suppl, p. TPS8619).

 

  1. Ghose A., Morrism J.C., Breneman J.C., Essell J. H., Wang J., & Benzaquen S., (2014) Medulloblastoma in an Adult with late Extraneural Metastases to the Mediastinum. Journal of investigative medicine high impact case reports, 2 (2), 2324709614532798.

 

  1. Berdeja, J. G., Hart, L. L., Mace, J. R., Arrowsmith, E. R., Essell, J.H., Owera, R.S., & Flinn, I.W. (2015). Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica, 100(5), 670-676.

 

  1. Berdeja, J.G, Gregory, T. B., Faber, E. A., Matous, J. V., Hart, L. L., Mace, J. R., Essell, J. H., & Flinn, I. W. (2015). A phase I/II study of the combination of panobinostat (PAN) and Carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM): comparison of two expansion cohorts. Blood, 126(23), 1825-1825.

 

  1. Abimanyu G., Morris, J. C., Breneman, J. C., Essell, J, Wang, J., and Benzaquen, S. (2014). Medulloblastoma in an Adult with Late Extraneural Metastases to the Mediastinum. Journal of Investigative Medicine HIGH IMPACT CASE REPORTS 2014 Apr-Jun 2(2):2324709614532798.

 

  1. Garcia-Manero G., Montalban-Bravo G., Berdeja J. G., Abaza Y., Jabbour E., Essell J., Lyons R. M., Ravandi F., Heller B., Dezern A. E., Babu S., Wright D., Anz B., Boccia R., Komrokji R. S., Kuriakose P., Reeves, J., Sekeres M.A., Kantarjian H.M., Ghalie R., Robuz G.J. (2017) Phase 2, randomized, double[1]blind study of pracinostat in combination with azacytidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 2017 May 15; 123 (6):994-1002. Curriculum Vitae James H. Essell, M.D. Oncology/Hematology Care, Inc. Last Updated: October 10, 2018 Page 8

 

  1. Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, Ye W, Assouline S, Sharman J. An open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myelmoma Leuk. 2018 Aug;18(8):e327-e331.

 

  1. Shaughnessy P, Bachier C, Grimley M, Freytes C, Callander, N, Essell JH, Flomenberg N, Selby G, Lemaistre CF. Denileukin Diftitox for the Treatment of Steroid-Resistant Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 11:188-193 (2005)©2005 American Society for Blood and Marrow Transplantation 1083-8791/05/110-0004$30.00/0doi:10.1016/j.bbmt.2004.11.022.

 

  1. Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine D, Niculescu L, Reeves J, Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. DOI: 10.1200/JCO.2014.58.7618 Journal of Clinical Oncology 33, no.33 (November 20, 2015)3921-3929.

 

  1. Berdeja JG, Bauer T, Arrowsmith E, Essell J, Murphy P, Reeves JA, Boccia, RV, Donnellan W, Flinn I. Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first- line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. British Journal of Haematology. 2017 Feb;177:254-262.

 

  1. Burris HA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O’Connor OA. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor in relapsed or refractory chronic lymphocytic leukemia and lymphoma: an open-label phase 1, dose-escalation, first-in-human study. The Lancet Oncology. 2018 April; 19(4): 486- 496.

 

  1. Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, and Ulrich Jäger, Effocacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research 10.1158/1078-0432.CCR-19-3061 Published May 2020.

 

  1. Fevzi F. Yalniz, Jesus G. Berdeja, Michal B. Maris, Roger M. Lyons, James A. Reeves Jr, James H. Essell, Prapti Patel, Mikkael Sekeres, Amanda Hughes, Silvia Mappa, Guillermo Garcia-Manero, A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. British Journal of Haematology. Https://doi.org/10.1111/bjh.16173 Published August 29, 2019.

 

  1. Sandy Smith, RN, MSN, AOCN1 ; James Essell, MD1,2 , Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting. Journal of Clinical Pathways, 2018;4(8):42-47, doi:10.25270/jcp.2018.10.00039 Published October 2018.

 

  1. Daniel J. Weisdorf MD 1 , Madan Jagasia MD2 , Amandeep Salhotra MD3 , Carlos R. Bachier MD4 , Behyar Zoghi MD5 , Aleksandr Lazaryan MD MPH PhD6 , James Essell MD7 , Laurie S. Green MEd8 , Olivier Schueller PhD8 , Zhongming Yang PhD8 , David A. Eiznhamer PhD8 , Sanjay K. Aggarwal MD8 , Bruce R. Blazar MD9 , Stephanie Lee MD, MPH10, KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) – Long-Term Follow-up of a Phase 2a Study (KD025-208). Science Direct Biology of Blood and Marrow Transplantation Volume 26, Issue 3, Supplement, March 2020, Pages S187-S188.

 

  1. Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Rapid Donor Identification Improves Survival in High-Risk First[1]Remission Patients With Acute Myeloid Leukemia JCO Oncol Pract. 2020 Jun;16(6):e464-e475. doi: 10.1200/JOP.19.00133. Epub 2020 Jan 27.PMID: 32048933 Curriculum Vitae James H. Essell, M.D. Oncology/Hematology Care, Inc. Last Updated: October 10, 2018 Page 9

 

  1. Yalniz FF, Berdeja JG, Maris MB, Lyons RM, Reeves JA Jr, Essell JH, Patel P, Sekeres M, Hughes A, Mappa S, Garcia-Manero A phase II study of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agents. G.Br J Haematol. 2020 Feb;188(3):404-412. doi: 10.1111/bjh.16173. Epub 2019 Aug 29.PMID: 31468521

 

  1. Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J, Lamanna N, Nagy Z, Tam CS, Stilgenbauer S, Ghia P, Delgado J, Lustgarten S, Weaver DT, Youssoufian H, Jäger, Efficacy and safety of Duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. U.Clin Cancer Res. 2020 May 1;26(9):2096-2103. doi: 10.1158/1078- 0432.CCR-19-3061. Epub 2020 Jan 21.PMID: 31964785

 

  1. Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. Rock2 inhibtion with belumosudil (KD025) for the treatment of chronic graft-versus -host disease. J Clin Oncol. 2021 Jun 10;39(17):1888-1898. doi: 10.1200/JCO.20.02754. Epub 2021 Apr 20.PMID: 33877856

 

  1. Donnellan W, Berdeja JG, Shipley D, Arrowsmith ER, Wright D, Lunin S, Brown R, Essell JH, Flinn IW. A phase II trial evaluating the safety of rapid infusion of ofatumumab in patients previously treated with chronic lymphocytic leukemia. Oncologist. 2017 Oct;22(10):1156-e111. doi: 10.1634/the oncologist.2017- 0236. Epub 2017 Jul 7.PMID: 28687625

 

  1. Sehgal A, Hoda D, Riedell P, Ghosh N, Hamadani M, Hildebrandt G, Godwin J, Reagan P, Wagner[1]Johnston N, Essell J. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (Pilot):an open-lable, phase 2 study. The Lancet Oncology 2022 Aug(vaol23) 1066 -107